

and evaluation of exclusively surface located epithelial antigen on vital unfixed cells, CETC were detected in most patients with early stage cancer. Subsequently cells could be stained with anti-ALDH-antibody and in situ hybridized for HER2/neu amplification and quantified repeatedly during neo/adjunct chemotherapy and during maintenance therapy with hormones or trastuzumab.

**Results:** 497 breast cancer patients were analyzed more than three times during the course of disease, 248 during neoadjuvant/adjunct chemotherapy, 249 during trastuzumab and or hormone therapy. Different pattern of therapy response were obtained with rapidly responding CETC changes over several logs in response to chemotherapy and slow and long-lasting changes extending over several years in response to hormone therapy and trastuzumab. Stem cell like staining was seen in a minor fraction of cells (1%) in about 10% of patients. An increase in cell numbers and in the fraction of HER2/neu amplified cells was under all treatment conditions unequivocally significantly correlated to highly increased risk of relapse.

**Conclusions:** CETC and subpopulation monitoring provides an invaluable tool for prompt gauging of systemic therapy in early stage solid tumours as a tool for therapy guidance and optimal personalized therapies to improve therapy results and spare unnecessary treatments.

5157

POSTER

#### Survival and prognostic factors in patients with early-stage breast cancer after conservation therapy

J. Galecki<sup>1</sup>, M. Nagadowska<sup>2</sup>, T. Pienkowski<sup>2</sup>, M. Grudzien-Kowalska<sup>1</sup>, J. Hiczer-Grzenkiewicz<sup>1</sup>, A. Niwinska<sup>2</sup>, R. Chmielewski<sup>2</sup>, Z. Mentrak<sup>2</sup>, E. Towplik<sup>2</sup>, W. Michalski<sup>3</sup>. <sup>1</sup>Maria Skłodowska – Curie Memorial Cancer, Radiotherapy Department, Warsaw, Poland; <sup>2</sup>Maria Skłodowska – Curie Memorial Cancer, Department of Breast Cancer and Reconstructive Surgery, Warsaw, Poland; <sup>3</sup>Maria Skłodowska – Curie Memorial Cancer, Clinical Trials and Biostatistics Unit, Warsaw, Poland

**Background:** To improve the access of patients with early breast cancer after conserving surgery to radiotherapy, in 1999 standard 5 weeks of whole breast irradiation was shortened to 3.5–4 weeks regimen and since then, according to international recommendations more often adjuvant chemotherapy regimens were used.

**Purpose:** Comparing disease-free and overall survival and prognostic factors in patients treated in two periods of time: between 1995–1998 and 1999–2002.

**Material and Methods:** The retrospective analysis included 552 early breast cancer patients consecutively treated between 1995–2002. During that time patients were entered to conservative treatment according to the same protocol. There were not differences in clinical and pathological characteristics between the two compared groups. Systemic treatment has been given in older and recent group in 50% and 82% of patients respectively. Cox regression survival analysis was used to study the effects of clinical, histological and some biological factors on disease-free and overall survival.

**Results:** 7-years disease free survival (DFS) and overall survival (OS) for all patients were 0.86% (0.82–0.89) and 0.92% (0.90–0.95) respectively. The Cox regression model by stepwise selection showed some parameters such as ductal carcinoma (HR 2.3; CI 1.3–4.4), G3 (HR 2.0; CI 1.2–3.4) negative steroid receptors (HR 10.1; CI 4.5–22.4), amplification HER2 (HR 7.4; CI 3.1–17.6) as independent significant predictors for DFS. Nodal index (HR 1.5; CI 1.0–2.1) and palpation of the tumor (HR 2.0; CI 0.95–4.1) appeared to have effect on DFS either but on the limit statistical significance ( $p > 0.05$ ). The significant independent predictors of OS on multivariate analysis were ductal carcinoma (HR 4.1; CI 1.6–10.6), G3 (HR 3.2; CI 1.6–6.4), negative steroid receptors (HR 9.4; CI 3.1–28.5) and amplification HER2 (HR 4.1; CI 1.2–15.2). Neither regimen of irradiation ( $p = 0.5$ ) nor period of treatment ( $p = 0.4$ ) were significant predictors of DFS. However the risk of death for patients treated between 1999–2002 was nearly three times more then for patients treated between 1995–1998 (HR 2.9; CI 1.1–7.4).

**Conclusion:** The prognosis of patients treated between 1999–2002 compared with 1995–1998 appeared worse in spite of more aggressive systemic management. Adjuvant treatment in early breast cancer should be based mostly on histological and biological features of malignancy because TNM classification is less useful in this group of patients.

5158

POSTER

#### Predictive value of circulating angiogenic factors in the neoadjuvant treatment of breast cancer

A. Chapelle<sup>1</sup>, P.J. Lamy<sup>2</sup>, G. Romieu<sup>1</sup>, S. Thezenas<sup>3</sup>, S. Pouderoux<sup>1</sup>, P.E. Colombo<sup>4</sup>, W. Jacot<sup>1</sup>. <sup>1</sup>CRLC Val d'Aurelle, Medical Oncology, Montpellier, France; <sup>2</sup>CRLC Val d'Aurelle, Department of Clinical Laboratory, Montpellier, France; <sup>3</sup>CRLC Val d'Aurelle, Biostatistics Unit, Montpellier, France; <sup>4</sup>CRLC Val d'Aurelle, Surgical Oncology Unit, Montpellier, France

**Background:** Neoadjuvant chemotherapy (NCT) is used in non-metastatic breast cancer to treat systemic disease earlier, try to achieve a complete pathological response (pCR), and increase the rate of conservative surgery. A useful strategy to improve knowledge about such treatments is the early identification of features associated with response or resistance. Over the last decade, research on angiogenic factors has greatly evolved. However, their exact prognostic and predictive value remain unclear, mainly due to the lack simultaneous evaluations. In order to identify the predictive value of a panel of circulating angiogenic factors, we evaluated the efficacy of a homogeneous NCT treatment in 79 patients treated in our centre. The association of a pCR with a serial determination of these different factors was evaluated in order to determine their predictive value.

**Material and Methods:** To study the predictive value of the serum level of a panel of angiogenic factors (VEGF, PlGF, VEGFR2, bFGF, TGF $\alpha$ , PDGF, Ang1, Ang2, Tie2) during NCT, a serial measurement of their value using ELISA or Luminex techniques was performed in a population of breast cancer patients treated by the association of 3 cycles of FEC100 then 4 taxane cycles. Serum samples were withdrawn before the first CT cycle, after 3 cycles of CT and before surgery. A correlation between classical clinicopathological factors, the initial levels of these factors, their kinetic variation and the achievement of a pCR was evaluated.

**Results:** 79 patients were evaluated. The clinicopathological characteristics of the population were classical of a neoadjuvant setting. 23% of the patients achieved a pCR. The following factors were significantly associated with a pCR in univariate analysis: ER positivity, PR positivity, low pretherapeutic TGF $\alpha$  level and the increase of VEGF levels between the first and the second sample. In multivariate analysis, ER positivity (OR = 0.233,  $p = 0.028$ ) and the increase of VEGF levels between the first and the second sample (OR = 5.13,  $p = 0.027$ ) were the only 2 factors significantly associated with a pCR, allowing us to develop an index able to predict the probability of pCR.

**Conclusions:** In such a NCT population, the initial kinetic variation of serum VEGF levels appears to be the most discriminating predictive angiogenic factor. Its association with ER status allows the development of a predictive index. The validation of these results on an independent population is ongoing.

5159

POSTER

#### The effects of E-Cadherin and bcl-2 on prognosis in patients with breast cancer

H. Kavgaci<sup>1</sup>, B. Yildiz<sup>1</sup>, E. Fidan<sup>1</sup>, A. Reis<sup>2</sup>, F. Ozdemir<sup>1</sup>, U. Cobanoglu<sup>2</sup>, G. Can<sup>3</sup>. <sup>1</sup>Karadeniz Technical University Medical Faculty, Medical Oncology, Trabzon, Turkey; <sup>2</sup>Karadeniz Technical University Medical Faculty, Pathology, Trabzon, Turkey; <sup>3</sup>Karadeniz Technical University Medical Faculty, Public Health, Trabzon, Turkey

**Background:** Breast cancer is the most common malignancy in women. Axillary lymph node involvement and tumor size are the most significant prognostic factors in breast cancer. However, more factors are needed for prognosis evaluation and individualization of treatment in these patients. Intracellular adhesion molecule E-cadherin, an antiapoptotic protein bcl-2, and p53 might have predictive and prognostic properties in breast cancer.

**Materials-Methods:** We have investigated the effects of E-cadherin, bcl-2, and p53 on disease free survival and overall survival in patients with breast cancer. Positivity of aforementioned genes was detected with immunohistochemistry staining. Seventy-six women patients with invasive ductal and lobular breast cancer who had received adjuvant therapy were included in the study. Chi-square test for the comparison of qualitative data, log-rank test for the comparison of variables that were used, Kaplan-Meier method for the evaluation of the relationship of these variables with disease free survival (DFS) and overall survival (OS), Cox-Regression test for multivariate analysis were used.

**Results:** Bcl-2, E-cadherin, and p53 expression in tumor tissue specimens were found 26.31%, 35.52%, and 9.21%. Mean duration of follow-up was 93.58 $\pm$ 3.40 months. Sixty-six patients (86.8%) were diagnosed as invasive ductal carcinoma, 10 patients (13.2%) were invasive lobular carcinoma. Median DFS (25%) and OS (16%) could not reach. In univariate analyses, we couldn't find any statistical significant between DFS and all parameters. Only there was statistical significant between OS and both of lymph node